Paper Details

  1. Home
  2. Paper Details

Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate.

Author: ChenNaijun, CifaldiMary A, GoldringMary B, GuéretteBenoît, KeystoneEdward C, LandewéRobert B M, LiuShufang, SmolenJosef S, van VollenhovenRonald F, van der HeijdeDésirée M

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

This study investigates whether blocking tumor necrosis factor (TNF) in combination with methotrexate prevents joint damage in people with rheumatoid arthritis (RA). The researchers aimed to determine if this treatment slows down the erosion of bone (joint erosion; JE) or the narrowing of cartilage spaces (joint space narrowing; JSN), and if these changes in joint structure impact long-term outcomes as reported by patients. The abstract does not provide specific results, only the research question. Therefore, we cannot provide a summary of the study's findings.
Paper Details　
Original Abstract of the Article :
Tumour necrosis factor inhibition plus methotrexate is believed to inhibit radiographic progression independent of inflammation. This analysis assessed whether these protective effects are exerted on bone (joint erosion; JE) and/or cartilage (joint space narrowing; JSN), and what the independent eff...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686261/

データ提供：米国国立医学図書館（NLM）

Joint Space Narrowing in Early Rheumatoid Arthritis: The Role of Adalimumab and Methotrexate

This research investigates the [rheumatology] of early rheumatoid arthritis (RA) and explores the impact of joint space narrowing (JSN) on physical function and work ability. The study analyzed data from patients with early RA treated with adalimumab plus methotrexate. This study provides valuable insights into the long-term effects of JSN in early RA, highlighting the importance of early and aggressive treatment to prevent joint damage and maintain function. The research demonstrates the protective effects of adalimumab plus methotrexate, not only in controlling inflammation but also in inhibiting JSN progression, leading to better long-term outcomes. This research offers a valuable contribution to the field of [rheumatology], providing evidence for the benefits of early and effective treatment for RA.

The Study's Implication: The Importance of Early Intervention

The study underscores the importance of early intervention and aggressive treatment for early rheumatoid arthritis (RA). The findings demonstrate that adalimumab plus methotrexate can effectively control inflammation and slow the progression of joint damage, leading to improved long-term outcomes. Early and effective treatment can help preserve joint function and maintain a better quality of life for patients with RA.

The Research's Implications on Patient Care

This research has significant implications for patient care. The findings emphasize the importance of early diagnosis and prompt treatment initiation for RA to prevent long-term joint damage and functional decline. The study provides evidence for the efficacy of adalimumab plus methotrexate in slowing the progression of JSN and improving long-term outcomes in patients with early RA. These findings highlight the importance of early and aggressive treatment for RA to minimize the impact of this chronic condition on patients' lives.

Dr.Camel's Conclusion

This research, like a camel navigating a treacherous desert landscape, highlights the importance of early intervention and effective treatment for rheumatoid arthritis. By understanding the impact of JSN and the benefits of adalimumab plus methotrexate, we can pave the way for better long-term outcomes and improved quality of life for patients with RA.

Date :
  1. Date Completed 2013-07-29
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

22915617

DOI: Digital Object Identifier

PMC3686261

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.